Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MIN-117 · WF-516

Small molecule · developed by Minerva Neurosciences

Phase 2 Most advanced trial (none active)
NERV Developer
1 Registered trials

What is MIN-117?

MIN-117 (also coded WF-516) is an oral capsule formulation studied in major depressive disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
WF-516
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Minerva Neurosciences (NERV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
APU2W4Y452

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03446846 Phase 2 Major Depressive Disorder Completed NERV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Major Depressive Disorder

More from Minerva Neurosciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NERV page.

Follow NERV, the company behind MIN-117

See NERV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NERV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.